H.R. 9090 — Introduced in House

I 117th CONGRESS 2d Session H. R. 9090 IN THE HOUSE OF REPRESENTATIVES September 30, 2022Ms. Dean introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend title XVIII of the Social Security Act to treat certain multimarker testing relating to ovarian cancer as reasonable and necessary for coverage under the Medicare program. 1. Short title This Act may be cited as the Diane Powis Ovarian Cancer Testing Access Act. 2. Certain multimarker testing related to ovarian cancer deemed reasonable and necessary for Medicare coverage Section 1834 of the Social Security Act (42 U.S.C. 1395m) is amended by adding at the end the following new subsection: (z) Certain multimarker testing related to ovarian cancer deemed reasonable and necessary (1) In general In the case of a clinical diagnostic laboratory test that is a multimarker test related to ovarian cancer that is furnished on or after January 1, 2023, to an individual who has been diagnosed with an ovarian adnexal mass, such test shall be deemed reasonable and necessary for purposes of section 1862(a)(1)(A) if the physician who orders such test determines such test is necessary for such individual and prescribes, dispenses, or administers such test for use in accordance with the labeling approved for such test by the Food and Drug Administration. (2) Multimarker test related to ovarian cancer defined For purposes of this subsection, the term multimarker test related to ovarian cancer means a test that evaluates more than one tumor marker with respect to ovarian cancer. .